Improving Medicines Availability Tops EU Regulators’ 2025 Workplan
The coordination group for EU mutual recognition and decentralized procedures is inviting stakeholder feedback on its priorities for the coming years.
You may also be interested in...
From Innovation Mindsets To Incentives And COVID-19 Lessons: How EU Pharma Legislation Should Evolve
If the EU wants to become a more competitive space for innovation it can take a few lessons from both the US and the COVID-10 pandemic, say European pharma industry representatives. Fostering better communication between regulators and companies is just one example.
Further analysis is under way, but first impressions by EU R&D industry group EFPIA of policy proposals for tackling drug shortages are not good.
A new European initiative will offer scientific advice, fee waivers and other support to not-for-profit and academic sponsors to help them find new uses for existing medicines and hook up with commercial companies to seek marketing authorization.